Gallman Cari, EVP of Corporate Affairs at Bristol-Myers Squibb (BMY), has demonstrated a consistent pattern of selling company stock without any offsetting purchases, according to SEC Form 4 filings. Over 28 reported transactions, all involving BMY, Gallman has sold shares totaling $298,278.54 while recording no buys. The most notable sales occurred on March 10, 2026, with three separate dispositions valued at $81,416.02, $23,811.48, and $24,953.95, followed by an earlier $106,642.36 sale on October 2, 2025. Smaller transactions, including a $26,572.26 sale on March 10, 2024, and a $5,647.95 sale the same day, further reinforce the trend.
The filings indicate that Gallman’s transactions are exclusively tied to BMY, with no diversification into other securities. The sales appear structured rather than concentrated, with multiple dispositions spread across different dates rather than large single exits. While some filings show transactions coded as gifts or other non-sale transfers (denoted by codes A, J, and M), all monetized transactions (code F) reflect a clear divestment pattern. The absence of any purchases over this period suggests a deliberate reduction in exposure to BMY equity, though the reasons remain undisclosed in regulatory filings. The activity underscores a one-directional approach, with no recent deviations from the selling trend.
AI-assisted summary